Диссертация (1174203), страница 33
Текст из файла (страница 33)
Frohm-Nilsson //European Journal of cancer. — 2013. — Т. 49 (12). — P. 2705—2716.99.Fabbrocini, G. Epidemiology of Skin Cancer: Role of Some EnvironmentalFactors / G. Fabbrocini, M. Triassi, M. C. Mauriello et al. // Cancers. — 2010. — T. 2(4). — P. 1980—1989.100. Fagnart, O. C. Particle counting immunoassay of S100 protein in serum.Possible relevance in tumors and ischemic disorders of the central nervous system / O. C.206Fagnart, C. J.
Sindic, C. Laterre // Clinical chemistry. — 1988. — T. 26 (1). — P. 35—39.101. Federman, D. Skin cancer screening and primary prevention: fact abdcontroversies / D. Federman, R. Kirsner, K. Viola // Clinics in dermatology. — 2013. —T. 31 (6). — P. 666—670.102. Ferlay, J. Cancer incidence and mortality patterns in Europe: estimates for40 countries in 2012 / J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al. // EuropeanJournal of cancer. — 2013. — T. 49 (6). — P.
1374—1403.103. Garbe, C. Risk factors for developing cutaneous melanoma and criteria foridentifying persons at risk: multicenter case-control study of the Central MalignantMelanoma Registry of the German Dermatological Society / C. Garbe, P. Büttner, J.Weiss et al. // The Journal of Investigating Dermatology. — 1994. — P. 102—107.104. Gareau, D. Automated detection of malignant features in confocalmicroscopy on superficial spreading melanoma versus nevi / D.
Gareau, R. Hennessy, E.Wan et al. // Journal of Biomedical optics. — 2010. — Т. 15 (6). doi: 10.1117/1.3524301.105. Gaynor, R. S100 protein is present in cultured human malignant melanomas/ R. Gaynor, R. Irie, D. Morton, H. R. Herschman // Nature. — 1980. — T. 286 (5771).— P. 400—401.106. Gaynor, R.
S100 protein: a marker for human malignant melanomas? / R.Gaynor, H. R. Herschman, R. Irie et al. // Lancet. — 1981. — T. 1 (8225). — P. 869—871.107. Gerger, A. Diagnostic applicability of in vivo confocal laser scanningmicroscopy in melanocytic skin tumors / A. Gerger, S. Koller, Kern T et al. // J InvestDermatol. — 2005. — T.
124. — P. 493—498.108. Gill, D. A prevalence of seborrheic keratosis in people aged 15—30 years /D. Gill, A. Dorevich, M. Robin // Archives of dermatology. — 2000. — Т. 136 (6). — P.759—762.109. Gkalpakiotis, S. Quantitative detection of melanoma-associated antigens bymultimarker real-time RT-PCR for molecular staging: results of a 5 years study / S.207Gkalpakiotis, P.
Arenberger, J. Kremen et al. // Experimental dermatology. — 2010. —Т. 19 (11). — P. 994—999.110. Glud M, Spectrophotometric intracutaneous analysis versus dermoscopy forthe diagnosis of pigmented skin lesions: prospective, double-blind study in a secondaryreference centre / M. Glud, R.
Gniadecki, KT. Drzewiecki // Melanoma research. — 2009.— T. 19 (3). — P. 176—179.111. Gogas, H. Biomarkers in melanoma / H. Gogas, A. M. Eggermont, A.Hauschild et al. // Annals of oncology. 2009. — Suppl. 6: vi8-13. doi:10.1093/annonc/mdp251.112. Gonzales, S. Clinical applications of reflectance confocal microscopy in themanagment of cutaneous tumors / S.
Gonzales // Actas Dermosifiliografica. — 2008. —Т. 99 (7). — P. 528—531.113. Gonzalez, S. In vivo reflectance-mode confocal microscopy in clinicaldermatology and cosmetology / S. Gonzalez, Y. Gilaberte-Calzada // InternationalJournal of Cosmetic Science. — 2008. — Т. 30 (1). — P. 1—17.114. Govindan, K. Assessment of nurse-led screening of pigmented lesions usingSIAscope / K. Govindan, J. Smith, L. Knowles et al. // J Plast Reconstr Aesthet Surgery.— 2007. — Т. 60.
— P. 639—645.115. Grimaldi, A. M. Novel approaches in melanoma prevention and therapy / A.M. Grimaldi, P. B. Cassidy, S. Leachmann et al. // Cancer treatment research. — 2014.— T. 159. — P. 443—455.116. Greaves, M. Cancer causation: the Darwinian downside of past success? /M. Greaves // The lancet oncology. — 2002.
— T. 3 (4). — P. 244—251.117. Grichnik, J. Доброкачественные новообразования и гиперплазиямеланоцитов / J. Grichnik // В кн.: Дерматология Фицпатрика в клиническойпрактике; под ред. Клауса Вольфа, Лоуэлла А., Голдсмита, Стивена И. Каца. — М.:Изд-во Панфилова. БИНОМ. Лаборатория знаний, 2012. — T. 2.
— С. 1201—1226.118. Guibert, P. Melanoma screening: report of a survey in occupational medicine/ P. Guibert, F. Mollat, M. Ligen, B. Dreno // Arhives of Dermatology. — 2000. — T.136 (2). — P. 199—202.208119. Guitera, P. In vivo reflectance confocal microscopy enhances secondaryevaluation of melanocytic lesions / P. Guitera, C. Longo, S. Seidenari et al. // J InvestDermatol. — 2009, Jan / — T. 129 (1).
— P. 131—138.120. Guo, H. B. Clinical significance of serum S100 in metastatic malignantmelanoma / H. B. Guo, B. Stoffel-Wagner, T. Bierwirth et al. // European journal ofcancer. — 1995. — T. 31A (11). — P. 1898—1902.121. Hacioglu, S. The value of spectrophotometric intracutaneous analysis in thenoninvasive diagnosis of nonmelanoma skin cancers.
/ S. Hacioglu, H. Saricaoglu, E. B.Baskan, S. I. Uner et al. // Clinical and experimental dermaology. — 2013. — V. 38 (5).— P. 464—469.122. Haggstrom, A. N. Prospective study of infantile hemangiomas: clinicalcharacteristics predicting complications and treatment / A. N. Haggstrom, B. A. Drolet,E. Baselga et al. // Pediatrics.
— 2006. — № 118 (3). — Р. 882—887.123. Hall, P. N. Use of a spectrophotometric intracutaneous analysis device in thereal-time diagnosis of melanoma / P. N. Hall, J. E. Hunter, F. M. Walter et al. // TheBritish Journal of Dermatology. — 2008. — T. 158 (2). — P.
422—424.124. Hamberg, A. P. Serum S100B is suitable for prediction and monitoring ofresponse to chemoimmunotherapy in metastatic malignant melanoma / A. P. Hamberg,C. M. Korse, J. M. Bonfrer et al. // Melanoma research. — 2003. — T. 13 (1). — P. 45—49.125. Harrington, E. Clyne B., Wesseling N. et al. Diagnosing malignantmelanoma in ambulatory care: a systematic review of clinical prediction rules / E.Harrington, B. Clyne, N.
Wesseling et al. // BMJ Open. — 2017. — T. 6,7 (3). doi:10.1136/bmjopen-2016-014096.126. Hauschild, A. Prognostic significance of serum S100B detection comparedwith routine blood parameters in advanced metastatic melanoma patients / Hauschild A.,Michaelsen J., Brenner W. et al. // Melanoma research.
— 1999. — T. 9 (2). — P. 155—161.209127. Henze, G. Serum S100-a marker for disease monitoring in metastaticmelanoma / G. Henze, R. Dummer, H. I. Joller-Jemelka et al. // Dermatology. — 1997.— T. 194 (3). — P. 208—212.128. Hofmann-Wellenhof, R. Reflectance confocal microscopy state-of-art andresearch overview / R. Hofmann-Wellenhof, E. M. Wurm, V. Ahlgrimm-Siess et al. //Seminars in Cutaneous Medicine and Surgery. — 2009. — Т. 28 (3). — P. 172—179.129.
Holt, P. Development of Clinical Practice Guidelines for the management ofCutaneous Melanoma and Melanoma in special sites: Handbook for chapter leaders andexpert working groups / P. Holt, M. Frommer. — Sydne: Sydney Health Projects Group,2006.130. Howlader, N. Improved estimates of cancer-specific survival rates frompopulation-based data / N.
Howlader, L. A. Ries, A. B. Mariotto et al. // Journal ofnational cancer institute. — 2010. — T. 102 (20). — P. 1584—1598.131. Huerta-Brogeras, M. Validation of dermoscopy as a real-time noninvasivediagnostic imaging technique for actinic keratosis / M. Huerta-Brogeras, O. Olmos, J.Borbujo et al. // Archives of Dermatology. — 2012. — Т. 148 (10). — P. 1159—1164.132.
Hunter, J. E. Triaging suspicious pigmented skin lesions in primary careusing the SIAscope / J. E. Hunter. — University of Cambridge, 2008. MD Thesis.133. Jacques, S. L. Modeling optical and thermal distributions in tissue duringlaser irradiation / S. L. Jacques, S. A. Prahl // Lasers in surgery and medicine. — 1987.— T 6 (6). — P. 494—503.134.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
